Luyan Pharma Stock Hits Day Low of CNY 11.07 Amid Price Pressure

Luyan Pharma Co., a small-cap player in the retailing sector, experienced significant volatility on July 17, 2026, with the stock declining by 10.0%. During the trading session, it reached an intraday low of CNY 11.07, reflecting a challenging day for the company. Despite this downturn, Luyan Pharma has shown resilience over the past year, achieving a return of 28.72%, outperforming the China Shanghai Composite, which recorded a gain of 7.03%. However, the year-to-date performance reveals a stark contrast, with Luyan Pharma down 47.73%, while the broader index has only declined by 5.16%. Financial metrics indicate that Luyan Pharma is net-debt free, yet it faces challenges with long-term growth, as evidenced by a modest annual sales growth rate of 5.57% and a slight decline in operating profit over the last five years. The company’s return on equity stands at 8.16%, suggesting limited profitability relative to shareholder funds. Additionally, the stock's price-to-book ratio of 1.28 indicates a relatively high valuation in the current market environment.